Effect on Immune function and pulmonary function of montelukast sodium combined with azithromycin in children with mycoplasma pneumonia

Objective: To observe the effect on Immune function and pulmonary function of montelukast sodium combined with azithromycin in children with mycoplasma pneumonia. Methods: A total of 100 cases of MPP children according to the inclusion sequence were divided into observation group and control grou...

Full description

Bibliographic Details
Main Authors: Yu-Ping Xia, Yuan Fangu
Format: Article
Language:English
Published: Editorial Board of Journal of Hainan Medical University 2016-09-01
Series:Journal of Hainan Medical University
Subjects:
Online Access:http://www.hnykdxxb.com/PDF/201618/12.pdf
id doaj-66f0a0eba60f4eb5bae0838d8132c9d8
record_format Article
spelling doaj-66f0a0eba60f4eb5bae0838d8132c9d82020-11-24T23:59:35ZengEditorial Board of Journal of Hainan Medical UniversityJournal of Hainan Medical University1007-12371007-12372016-09-0122184851Effect on Immune function and pulmonary function of montelukast sodium combined with azithromycin in children with mycoplasma pneumoniaYu-Ping Xia0Yuan Fangu1Department of Emergency Pediatrics, Zhenjiang First People's Hospital, Zhenjiang 212002, Jiangsu, ChinaDepartment of Emergency Pediatrics, Zhenjiang First People's Hospital, Zhenjiang 212002, Jiangsu, ChinaObjective: To observe the effect on Immune function and pulmonary function of montelukast sodium combined with azithromycin in children with mycoplasma pneumonia. Methods: A total of 100 cases of MPP children according to the inclusion sequence were divided into observation group and control group, 50 cases in each. The control group was given azithromycin, and the observation group was given montelukast sodium based on the control group. After 2 weeks, to observe the changes of immune function (IgG, IgA, IgM and CD4+, CD8+, CD4+/CD8+) and pulmonary function (FEV1, FVC, PEV and MEF50) between the two groups. Results: (1) After treatment, IgG, IgM of the two groups decreased and IgA increased obviously; CD4+, CD4+/CD8+ of the two groups increased and CD8+ decreased obviously; observation group after treatment, levels of IgM, IgA, CD8+ were (1.10+0.39) g/L, (1.14+0.38) g/L, (24.23+4.53)% , respectively, which was significantly lower than that of the control group, levels of IgG, CD4+ and CD4+/CD8+ were (9.73±2.72) g/L, (35.54±8.30)% and (1.43±0.40)% ,respectively, which was significantly higher than that of the control group after treatment. At the same time, the difference has statistical significance. (2) After treatment, FEV1, FVC, PEV and MEF50 of the two groups increased obviously, observation group after treatment, FEV1, FVC, PEV and BPT were (2.29±0.53) L, (78.52±8.35)%, (4.27±0.67) L/S, (71.43±9.03) L/S, respectively, which was significantly higher than that of the control group, the difference was statistically significant. Conclusion: combination of montelukast sodium have greater regulation of immune function disorder and more conducive to improving lung function when Azithromycin treatment for child MPP.http://www.hnykdxxb.com/PDF/201618/12.pdfChildrenMycoplasma pneumoniaAzithromycinMontelukast sodiumImmune functionPulmonary function
collection DOAJ
language English
format Article
sources DOAJ
author Yu-Ping Xia
Yuan Fangu
spellingShingle Yu-Ping Xia
Yuan Fangu
Effect on Immune function and pulmonary function of montelukast sodium combined with azithromycin in children with mycoplasma pneumonia
Journal of Hainan Medical University
Children
Mycoplasma pneumonia
Azithromycin
Montelukast sodium
Immune function
Pulmonary function
author_facet Yu-Ping Xia
Yuan Fangu
author_sort Yu-Ping Xia
title Effect on Immune function and pulmonary function of montelukast sodium combined with azithromycin in children with mycoplasma pneumonia
title_short Effect on Immune function and pulmonary function of montelukast sodium combined with azithromycin in children with mycoplasma pneumonia
title_full Effect on Immune function and pulmonary function of montelukast sodium combined with azithromycin in children with mycoplasma pneumonia
title_fullStr Effect on Immune function and pulmonary function of montelukast sodium combined with azithromycin in children with mycoplasma pneumonia
title_full_unstemmed Effect on Immune function and pulmonary function of montelukast sodium combined with azithromycin in children with mycoplasma pneumonia
title_sort effect on immune function and pulmonary function of montelukast sodium combined with azithromycin in children with mycoplasma pneumonia
publisher Editorial Board of Journal of Hainan Medical University
series Journal of Hainan Medical University
issn 1007-1237
1007-1237
publishDate 2016-09-01
description Objective: To observe the effect on Immune function and pulmonary function of montelukast sodium combined with azithromycin in children with mycoplasma pneumonia. Methods: A total of 100 cases of MPP children according to the inclusion sequence were divided into observation group and control group, 50 cases in each. The control group was given azithromycin, and the observation group was given montelukast sodium based on the control group. After 2 weeks, to observe the changes of immune function (IgG, IgA, IgM and CD4+, CD8+, CD4+/CD8+) and pulmonary function (FEV1, FVC, PEV and MEF50) between the two groups. Results: (1) After treatment, IgG, IgM of the two groups decreased and IgA increased obviously; CD4+, CD4+/CD8+ of the two groups increased and CD8+ decreased obviously; observation group after treatment, levels of IgM, IgA, CD8+ were (1.10+0.39) g/L, (1.14+0.38) g/L, (24.23+4.53)% , respectively, which was significantly lower than that of the control group, levels of IgG, CD4+ and CD4+/CD8+ were (9.73±2.72) g/L, (35.54±8.30)% and (1.43±0.40)% ,respectively, which was significantly higher than that of the control group after treatment. At the same time, the difference has statistical significance. (2) After treatment, FEV1, FVC, PEV and MEF50 of the two groups increased obviously, observation group after treatment, FEV1, FVC, PEV and BPT were (2.29±0.53) L, (78.52±8.35)%, (4.27±0.67) L/S, (71.43±9.03) L/S, respectively, which was significantly higher than that of the control group, the difference was statistically significant. Conclusion: combination of montelukast sodium have greater regulation of immune function disorder and more conducive to improving lung function when Azithromycin treatment for child MPP.
topic Children
Mycoplasma pneumonia
Azithromycin
Montelukast sodium
Immune function
Pulmonary function
url http://www.hnykdxxb.com/PDF/201618/12.pdf
work_keys_str_mv AT yupingxia effectonimmunefunctionandpulmonaryfunctionofmontelukastsodiumcombinedwithazithromycininchildrenwithmycoplasmapneumonia
AT yuanfangu effectonimmunefunctionandpulmonaryfunctionofmontelukastsodiumcombinedwithazithromycininchildrenwithmycoplasmapneumonia
_version_ 1725447250515066880